Cargando…

Opioid-Free Labor Analgesia: Dexmedetomidine as an Adjuvant Combined with Ropivacaine

BACKGROUND: Side effects of the use of opioid analgesics during painless delivery are the main factors that affect rapid postpartum recovery. Opioid use can result in dangerous respiratory depression in the patient. Opioids can also disrupt the baby's breathing and heart rate. The nonopioid ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Wei, Wang, Jie, Zhang, Zhiguo, He, Haiying, Li, Huiwen, Hou, Ruili, Zhao, Liping, Gaichu, Daniel Muthee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983222/
https://www.ncbi.nlm.nih.gov/pubmed/35392153
http://dx.doi.org/10.1155/2022/2235025
_version_ 1784681938115624960
author Gao, Wei
Wang, Jie
Zhang, Zhiguo
He, Haiying
Li, Huiwen
Hou, Ruili
Zhao, Liping
Gaichu, Daniel Muthee
author_facet Gao, Wei
Wang, Jie
Zhang, Zhiguo
He, Haiying
Li, Huiwen
Hou, Ruili
Zhao, Liping
Gaichu, Daniel Muthee
author_sort Gao, Wei
collection PubMed
description BACKGROUND: Side effects of the use of opioid analgesics during painless delivery are the main factors that affect rapid postpartum recovery. Opioid use can result in dangerous respiratory depression in the patient. Opioids can also disrupt the baby's breathing and heart rate. The nonopioid analgesic dexmedetomidine, a new a2-adrenergic agonist, possesses higher selectivity, greater analgesic effects, and fewer side effects. Moreover, epidural administration of dexmedetomidine also reduces local anesthetic consumption. OBJECTIVE: Our study aims to compare the analgesic effects as well as the side effects of ropivacaine with dexmedetomidine against sufentanyl as an epidural labor analgesia. METHODS: This study is a randomized, double-blinded, controlled trial (registration no. ChiCTR2200055360) involving 120 primiparous (a woman who has given birth once), singleton pregnancy women who are greater than 38 weeks into gestation and have requested epidural labor analgesia. The participants were randomized to receive 0.1% ropivacaine with sufentanyl (0.4 μg/ml) or dexmedetomidine (0.4 μg/ml). The primary outcomes included Visual Analogue Score (VAS), duration of first epidural infusions, the requirement of additional PCEA bolus, and adverse reactions during labor analgesia. RESULTS: Of the 120 subjects who consented, 91 parturient women (women in the condition of labor) had complete data for analysis. Demographics and VAS, as well as maternal and fetal outcomes, were similar between the groups. The duration of first epidural infusions in dexmedetomidine was significantly longer than sufentanyl (median value: 115 vs 68 min, P < 0.01); the parturient women who received dexmedetomidine and who required additional PCEA bolus were fewer in comparison to those who received sufentanyl (27.5% vs 49.0%, P < 0.05). Furthermore, the incidence of pruritus in the dexmedetomidine group was lower in comparison to the sufentanyl group (0% vs 11.8%, P < 0.05). CONCLUSIONS: Dexmedetomidine, a nonopioid, is superior to the opioid analgesic sufentanyl in providing a prolonged analgesic effect as an epidural during labor. It also reduces local anesthetic consumption and has fewer side effects. The trial is registered with ChiCTR2200055360.
format Online
Article
Text
id pubmed-8983222
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89832222022-04-06 Opioid-Free Labor Analgesia: Dexmedetomidine as an Adjuvant Combined with Ropivacaine Gao, Wei Wang, Jie Zhang, Zhiguo He, Haiying Li, Huiwen Hou, Ruili Zhao, Liping Gaichu, Daniel Muthee J Healthc Eng Research Article BACKGROUND: Side effects of the use of opioid analgesics during painless delivery are the main factors that affect rapid postpartum recovery. Opioid use can result in dangerous respiratory depression in the patient. Opioids can also disrupt the baby's breathing and heart rate. The nonopioid analgesic dexmedetomidine, a new a2-adrenergic agonist, possesses higher selectivity, greater analgesic effects, and fewer side effects. Moreover, epidural administration of dexmedetomidine also reduces local anesthetic consumption. OBJECTIVE: Our study aims to compare the analgesic effects as well as the side effects of ropivacaine with dexmedetomidine against sufentanyl as an epidural labor analgesia. METHODS: This study is a randomized, double-blinded, controlled trial (registration no. ChiCTR2200055360) involving 120 primiparous (a woman who has given birth once), singleton pregnancy women who are greater than 38 weeks into gestation and have requested epidural labor analgesia. The participants were randomized to receive 0.1% ropivacaine with sufentanyl (0.4 μg/ml) or dexmedetomidine (0.4 μg/ml). The primary outcomes included Visual Analogue Score (VAS), duration of first epidural infusions, the requirement of additional PCEA bolus, and adverse reactions during labor analgesia. RESULTS: Of the 120 subjects who consented, 91 parturient women (women in the condition of labor) had complete data for analysis. Demographics and VAS, as well as maternal and fetal outcomes, were similar between the groups. The duration of first epidural infusions in dexmedetomidine was significantly longer than sufentanyl (median value: 115 vs 68 min, P < 0.01); the parturient women who received dexmedetomidine and who required additional PCEA bolus were fewer in comparison to those who received sufentanyl (27.5% vs 49.0%, P < 0.05). Furthermore, the incidence of pruritus in the dexmedetomidine group was lower in comparison to the sufentanyl group (0% vs 11.8%, P < 0.05). CONCLUSIONS: Dexmedetomidine, a nonopioid, is superior to the opioid analgesic sufentanyl in providing a prolonged analgesic effect as an epidural during labor. It also reduces local anesthetic consumption and has fewer side effects. The trial is registered with ChiCTR2200055360. Hindawi 2022-03-29 /pmc/articles/PMC8983222/ /pubmed/35392153 http://dx.doi.org/10.1155/2022/2235025 Text en Copyright © 2022 Wei Gao et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gao, Wei
Wang, Jie
Zhang, Zhiguo
He, Haiying
Li, Huiwen
Hou, Ruili
Zhao, Liping
Gaichu, Daniel Muthee
Opioid-Free Labor Analgesia: Dexmedetomidine as an Adjuvant Combined with Ropivacaine
title Opioid-Free Labor Analgesia: Dexmedetomidine as an Adjuvant Combined with Ropivacaine
title_full Opioid-Free Labor Analgesia: Dexmedetomidine as an Adjuvant Combined with Ropivacaine
title_fullStr Opioid-Free Labor Analgesia: Dexmedetomidine as an Adjuvant Combined with Ropivacaine
title_full_unstemmed Opioid-Free Labor Analgesia: Dexmedetomidine as an Adjuvant Combined with Ropivacaine
title_short Opioid-Free Labor Analgesia: Dexmedetomidine as an Adjuvant Combined with Ropivacaine
title_sort opioid-free labor analgesia: dexmedetomidine as an adjuvant combined with ropivacaine
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983222/
https://www.ncbi.nlm.nih.gov/pubmed/35392153
http://dx.doi.org/10.1155/2022/2235025
work_keys_str_mv AT gaowei opioidfreelaboranalgesiadexmedetomidineasanadjuvantcombinedwithropivacaine
AT wangjie opioidfreelaboranalgesiadexmedetomidineasanadjuvantcombinedwithropivacaine
AT zhangzhiguo opioidfreelaboranalgesiadexmedetomidineasanadjuvantcombinedwithropivacaine
AT hehaiying opioidfreelaboranalgesiadexmedetomidineasanadjuvantcombinedwithropivacaine
AT lihuiwen opioidfreelaboranalgesiadexmedetomidineasanadjuvantcombinedwithropivacaine
AT houruili opioidfreelaboranalgesiadexmedetomidineasanadjuvantcombinedwithropivacaine
AT zhaoliping opioidfreelaboranalgesiadexmedetomidineasanadjuvantcombinedwithropivacaine
AT gaichudanielmuthee opioidfreelaboranalgesiadexmedetomidineasanadjuvantcombinedwithropivacaine